TY - JOUR
T1 - The D2 and D3 sublineages of human papilloma virus 16-positive cervical cancer in Guatemala differ in integration rate and age of diagnosis
AU - Lou, Hong
AU - Boland, Joseph F.
AU - Torres-Gonzalez, Edmundo
AU - Albanez, Anaseidy
AU - Zhou, Weiyin
AU - Steinberg, Mia K.
AU - Diaw, Lena
AU - Mitchell, Jason
AU - Roberson, David
AU - Cullen, Michael
AU - Garland, Lisa
AU - Bass, Sara
AU - Burk, Robert D.
AU - Yeager, Meredith
AU - Wentzensen, Nicolas
AU - Schiffman, Mark
AU - Freites, Enrique Alvirez
AU - Gharzouzi, Eduardo
AU - Mirabello, Lisa
AU - Dean, Michael
N1 - Funding Information:
We thank the patients who agreed to participate in this study and the physicians and staff that helped recruit subjects and collect samples. We thank Esther Avila, Lineth Boror, and Paty Zaid for sample and data collection and shipping, and the Liga Contra Cancer. This work was supported, in part, by project LTG-10410 of the NIH Intramural Research Program.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/9/15
Y1 - 2020/9/15
N2 - Human papillomavirus (HPV) 16 displays substantial sequence variation; four HPV16 lineages (A, B, C, and D) have been described as well as multiple sublineages. To identify molecular events associated with HPV16 carcinogenesis, we evaluated viral variation, the integration of HPV16, and somatic mutation in 96 cervical cancer samples from Guatemala. A total of 65% (62/96) of the samples had integrated HPV16 sequences and integration was associated with an earlier age of diagnosis and premenopausal disease. HPV16 integration sites were broadly distributed in the genome, but in one tumor, HPV16 integrated into the promoter of the IFN regulatory factor 4 (IRF4) gene, which plays an important role in the regulation of the IFN response to viral infection. The HPV16 D2 and D3 sublineages were found in 23% and 30% of the tumors, respectively, and were significantly associated with adenocarcinoma. D2-positive tumors had a higher rate of integration, earlier age of diagnosis, and a lower rate of somatic mutation, whereas D3-positive tumors were less likely to integrate, had later age of diagnosis, and exhibited a higher rate of somatic mutation. In conclusion, Guatemalan cervical tumors have a high frequency of very high-risk HPV16 D2 and D3 sublineages harboring distinct histology, which may help guide future therapeutic strategies to target the tumor and reduce recurrence.
AB - Human papillomavirus (HPV) 16 displays substantial sequence variation; four HPV16 lineages (A, B, C, and D) have been described as well as multiple sublineages. To identify molecular events associated with HPV16 carcinogenesis, we evaluated viral variation, the integration of HPV16, and somatic mutation in 96 cervical cancer samples from Guatemala. A total of 65% (62/96) of the samples had integrated HPV16 sequences and integration was associated with an earlier age of diagnosis and premenopausal disease. HPV16 integration sites were broadly distributed in the genome, but in one tumor, HPV16 integrated into the promoter of the IFN regulatory factor 4 (IRF4) gene, which plays an important role in the regulation of the IFN response to viral infection. The HPV16 D2 and D3 sublineages were found in 23% and 30% of the tumors, respectively, and were significantly associated with adenocarcinoma. D2-positive tumors had a higher rate of integration, earlier age of diagnosis, and a lower rate of somatic mutation, whereas D3-positive tumors were less likely to integrate, had later age of diagnosis, and exhibited a higher rate of somatic mutation. In conclusion, Guatemalan cervical tumors have a high frequency of very high-risk HPV16 D2 and D3 sublineages harboring distinct histology, which may help guide future therapeutic strategies to target the tumor and reduce recurrence.
UR - http://www.scopus.com/inward/record.url?scp=85100347333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100347333&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-0029
DO - 10.1158/0008-5472.CAN-20-0029
M3 - Article
C2 - 32631904
AN - SCOPUS:85100347333
SN - 0008-5472
VL - 80
SP - 3803
EP - 3809
JO - Cancer Research
JF - Cancer Research
IS - 18
ER -